FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894567029> ?p ?o ?g. }

• W2894567029 endingPage "34793" @default.
• W2894567029 startingPage "34784" @default.
• W2894567029 abstract "// Mariko Ishibashi 1, 2 , Saori Soeda 1 , Makoto Sasaki 3 , Hiroshi Handa 4 , Yoichi Imai 5 , Norina Tanaka 6 , Sakae Tanosaki 7 , Shigeki Ito 8 , Takeshi Odajima 9 , Hiroki Sugimori 10 , Toshio Asayama 1 , Mika Sunakawa 1 , Yuta Kaito 1 , Ryosuke Kinoshita 1 , Yasuko Kuribayashi 1 , Asaka Onodera 1 , Keiichi Moriya 1 , Junji Tanaka 6 , Yutaka Tsukune 3 , Norio Komatsu 3 , Koiti Inokuchi 1 and Hideto Tamura 1 1 Department of Hematology, Nippon Medical School, Tokyo, Japan 2 Department of Microbiology and Immunology, Nippon Medical School, Tokyo, Japan 3 Division of Hematology, Department of Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan 4 Department of Hematology, Gunma University, Gunma, Japan 5 Department of Hematology and Oncology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan 6 Department of Hematology, Tokyo Women’s Medical University, Tokyo, Japan 7 Department of Hematology, The Fraternity Memorial Hospital, Tokyo, Japan 8 Department of Clinical Oncology, Iwate Medical University School of Medicine, Iwate, Japan 9 Faculty of Health Science, Daito Bunka University Graduate School of Sports and Health Science, Tokyo, Japan 10 Department of Preventive Medicine, Daito Bunka University Graduate School of Sports and Health Science, Saitama, Japan Correspondence to: Hideto Tamura, email: tam@nms.ac.jp Keywords: multiple myeloma; SLAMF7; soluble form; CS1; elotuzumab Received: May 17, 2018     Accepted: September 17, 2018     Published: October 05, 2018 ABSTRACT The signaling lymphocytic activation molecule family (SLAMF7; also known as CS1 or CD319) is highly expressed on plasma cells from multiple myeloma (MM) as well as natural killer (NK) cells and is a well-known therapeutic target of elotuzumab. The objective of this study was to evaluate the clinical significance of serum soluble SLAMF7 (sSLAMF7) levels in patients with MM (n=103) and furthermore the impact of sSLMF7 on the antitumor activity of anti-SLAMF7 antibody. Thirty-one percent of MM patients, but not patients with monoclonal gammopathy of undetermined significance and healthy controls, had detectable levels of serum sSLAMF7, which were significantly increased in advanced MM patients. Further, MM in sSLAMF7-postive patients exhibited aggressive clinical characteristics with shorter progression-free survival times in comparison with sSLAMF7-negative patients. In responders to MM therapy, the levels of sSLAMF7 were undetectable or decreased compared with those before treatment. In addition, the anti-SLAMF7 antibody-mediated antibody-dependent cellular cytotoxicity of NK cells against MM cell lines was inhibited by recombinant SLAMF7 protein. Thus, our findings suggest that high concentrations of sSLAMF7, which could transiently suppress the therapeutic effects of elotuzumab, may be a useful indicator of disease progression in MM patients." @default.
• W2894567029 created "2018-10-12" @default.
• W2894567029 creator A5004672910 @default.
• W2894567029 creator A5005208937 @default.
• W2894567029 creator A5011532171 @default.
• W2894567029 creator A5012056114 @default.
• W2894567029 creator A5014421951 @default.
• W2894567029 creator A5015983203 @default.
• W2894567029 creator A5020985742 @default.
• W2894567029 creator A5021620288 @default.
• W2894567029 creator A5031116384 @default.
• W2894567029 creator A5035574560 @default.
• W2894567029 creator A5036492824 @default.
• W2894567029 creator A5051413568 @default.
• W2894567029 creator A5055814626 @default.
• W2894567029 creator A5056294010 @default.
• W2894567029 creator A5066174292 @default.
• W2894567029 creator A5067111637 @default.
• W2894567029 creator A5067803439 @default.
• W2894567029 creator A5069310805 @default.
• W2894567029 creator A5082834482 @default.
• W2894567029 creator A5087133884 @default.
• W2894567029 creator A5087601635 @default.
• W2894567029 creator A5090658715 @default.
• W2894567029 date "2018-10-05" @default.
• W2894567029 modified "2023-09-29" @default.
• W2894567029 title "Clinical impact of serum soluble SLAMF7 in multiple myeloma" @default.
• W2894567029 cites W1836624136 @default.
• W2894567029 cites W1959773306 @default.
• W2894567029 cites W1969110349 @default.
• W2894567029 cites W1992966390 @default.
• W2894567029 cites W2000815213 @default.
• W2894567029 cites W2002048624 @default.
• W2894567029 cites W2004543856 @default.
• W2894567029 cites W2006382315 @default.
• W2894567029 cites W2012426855 @default.
• W2894567029 cites W2013296669 @default.
• W2894567029 cites W2043426590 @default.
• W2894567029 cites W2049270621 @default.
• W2894567029 cites W2073125824 @default.
• W2894567029 cites W2095255742 @default.
• W2894567029 cites W2102750142 @default.
• W2894567029 cites W2120474651 @default.
• W2894567029 cites W2126120941 @default.
• W2894567029 cites W2128192762 @default.
• W2894567029 cites W2128644254 @default.
• W2894567029 cites W2158020131 @default.
• W2894567029 cites W2201190784 @default.
• W2894567029 cites W2295721179 @default.
• W2894567029 cites W2344651272 @default.
• W2894567029 cites W2344653410 @default.
• W2894567029 cites W2414490209 @default.
• W2894567029 cites W2513838373 @default.
• W2894567029 cites W2528730592 @default.
• W2894567029 cites W2549893547 @default.
• W2894567029 cites W2562243521 @default.
• W2894567029 cites W2588053707 @default.
• W2894567029 cites W2732548543 @default.
• W2894567029 cites W2786794342 @default.
• W2894567029 cites W4211058750 @default.
• W2894567029 cites W4252175385 @default.
• W2894567029 doi "https://doi.org/10.18632/oncotarget.26196" @default.
• W2894567029 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6205184" @default.
• W2894567029 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30410677" @default.
• W2894567029 hasPublicationYear "2018" @default.
• W2894567029 type Work @default.
• W2894567029 sameAs 2894567029 @default.
• W2894567029 citedByCount "26" @default.
• W2894567029 countsByYear W28945670292019 @default.
• W2894567029 countsByYear W28945670292020 @default.
• W2894567029 countsByYear W28945670292021 @default.
• W2894567029 countsByYear W28945670292022 @default.
• W2894567029 countsByYear W28945670292023 @default.
• W2894567029 crossrefType "journal-article" @default.
• W2894567029 hasAuthorship W2894567029A5004672910 @default.
• W2894567029 hasAuthorship W2894567029A5005208937 @default.
• W2894567029 hasAuthorship W2894567029A5011532171 @default.
• W2894567029 hasAuthorship W2894567029A5012056114 @default.
• W2894567029 hasAuthorship W2894567029A5014421951 @default.
• W2894567029 hasAuthorship W2894567029A5015983203 @default.
• W2894567029 hasAuthorship W2894567029A5020985742 @default.
• W2894567029 hasAuthorship W2894567029A5021620288 @default.
• W2894567029 hasAuthorship W2894567029A5031116384 @default.
• W2894567029 hasAuthorship W2894567029A5035574560 @default.
• W2894567029 hasAuthorship W2894567029A5036492824 @default.
• W2894567029 hasAuthorship W2894567029A5051413568 @default.
• W2894567029 hasAuthorship W2894567029A5055814626 @default.
• W2894567029 hasAuthorship W2894567029A5056294010 @default.
• W2894567029 hasAuthorship W2894567029A5066174292 @default.
• W2894567029 hasAuthorship W2894567029A5067111637 @default.
• W2894567029 hasAuthorship W2894567029A5067803439 @default.
• W2894567029 hasAuthorship W2894567029A5069310805 @default.
• W2894567029 hasAuthorship W2894567029A5082834482 @default.
• W2894567029 hasAuthorship W2894567029A5087133884 @default.
• W2894567029 hasAuthorship W2894567029A5087601635 @default.
• W2894567029 hasAuthorship W2894567029A5090658715 @default.
• W2894567029 hasBestOaLocation W28945670291 @default.
• W2894567029 hasConcept C126322002 @default.

• next